Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 4/20 | 0.73 |
| ▸ | PRKDC | P78527 | 4/20 | 0.73 |
| ▸ | FYN | P06241 | 6/20 | 0.70 |
| ▸ | SRC | P12931 | 6/20 | 0.64 |
| ▸ | ABL1 | P00519 | 2/20 | 0.63 |
| ▸ | EGFR | P00533 | 2/20 | 0.62 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.60 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.60 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.60 |
| ▸ | KDR | P35968 | 2/20 | 0.60 |
| ▸ | HCK | P08631 | 1/20 | 0.60 |
| ▸ | MTOR | P42345 | 1/20 | 0.60 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.60 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | LYN | P07948 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15826975 | 0.87 | FYN (0.68) | PIK3CDPRKDCFYNSRCABL1 | |
| SCHEMBL14086355 | 0.87 | SRC (0.66) | PIK3CDPRKDCFYNSRCABL1 | |
| SCHEMBL13019687 | 0.86 | CYP1A2 (0.75) | PIK3CDPRKDCFYNSRCABL1 | |
| SCHEMBL21048473 | 0.84 | PIK3CD (1.00) | PIK3CDPRKDCSRCABL1EGFR | |
| SCHEMBL30385963 | 0.84 | PIK3CD (1.00) | PIK3CDPRKDCSRCABL1EGFR | |
| SCHEMBL409570 | 0.83 | SRC (0.61) | PIK3CDPRKDCFYNSRCABL1 | |
| SCHEMBL12551792 | 0.83 | SRC (0.64) | PIK3CDPRKDCFYNSRCABL1 | |
| SCHEMBL17725997 | 0.83 | FYN (1.00) | PIK3CDPRKDCFYNSRCABL1 | |
| SCHEMBL29678005 | 0.82 | PIK3CD (0.74) | PIK3CDPRKDCFYNSRCABL1 | |
| SCHEMBL14471386 | 0.82 | PIK3CD (0.63) | PIK3CDPRKDCFYNSRCABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9944639-B2 | Quinolizinone derivatives as PI3K inhibitors | LUPIN LIMITED (IN) | 2018-04-17 | — | — | US | disclosed |
| US-20170137421-A1 | QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS | LUPIN LIMITED (IN) | 2017-05-18 | — | — | US | disclosed |
| US-20150353557-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2015-12-10 | — | — | US | disclosed |
| US-8962635-B2 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962831-B2 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8946241-B2 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8759358-B1 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2014-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353557-A1 | TYROSINE KINASE INHIBITORS | BMX, ITK, BLK | PIK3CD 389/4885PRKDC 140/4885FYN 28/4885 |
| US-20170137421-A1 | QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS | PIK3R5, PIK3R1, PIK3R4 | PIK3CD 5/4885PRKDC 1298/4885FYN 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.